Background:
- Prostate cancer is the second leading cause of cancer deaths in American men. A chemical
called a radiotracer helps doctors get images of this type of cancer. Researchers want to
test a radiotracer called
N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC)
(18F-DCFBC).
Objective:
- To see if the radiotracer 18F-DCFBC can identify sites of prostate cancer in the body.
Eligibility:
- Men ages 18 and over with prostate cancer. The cancer must be newly diagnosed, have
relapsed, or has spread outside the prostate.
Design:
- Participants will be screened with physical exam and medical history. They will give a
blood sample.
- Participants will be divided into three groups.
Group 1: people with cancer only in the prostate scheduled for surgical prostate removal or
biopsy at National Institutes of Health (NIH).
Group 2: people who had their prostate removed or had radiation therapy and now have a rising
prostate-specific antigen (PSA) without other signs of disease.
Group 3: people whose cancer has spread to other areas of the body.
- Participants will have 18F-DCFBC injected into a vein then imaged in a positron emission
tomography (PET)/computed tomography (CT) camera. During the scans, they will lie on
their back on the scanner table.
- Group 1 will have a magnetic resonance imaging (MRI) scan. A tube will be placed in the
rectum. Coils may be wrapped around the outside of the pelvis. Participants will have a
contrast agent injected through an intravenous line.
- Group 3 will have another PET/CT scan with a different radiotracer, 18F NaF, within 21
days of the 18F-DCFBC scan to look for prostate cancer in the bone.
- Group 3 will repeat the two PET/CT scans 4-6 months after the initial scans.
- A few days after each scan, participants will be contacted for follow-up.